Literature DB >> 19289269

Guanidinoacetate methyltransferase deficiency (GAMT).

Neil Gordon1.   

Abstract

An increasing number of disorders of metabolism are becoming amenable to the treatment, and GAMT deficiency is one of them. The symptoms and signs are reviewed, emphasising that delayed language development is a particular feature. Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders. The condition is inherited in an autosomal recessive manner, and mutations in the GAMT gene severely affect the activity of guanidinoacetate. The MRI scan shows an increased signal in the globus pallidus, and the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine. Other methods of diagnosis are discussed. Treatment is based on giving creatine supplementation orally and a low-protein diet with restricted arginine and increased ornithine. This results in improvement of many of the symptoms, especially of the epileptic seizures and the abnormal movements. It is justifiable to consider this condition in any patient with unexplained learning disorders. 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289269     DOI: 10.1016/j.braindev.2009.01.008

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

1.  Non-derivatized Assay for the Simultaneous Detection of Amino Acids, Acylcarnitines, Succinylacetone, Creatine, and Guanidinoacetic Acid in Dried Blood Spots by Tandem Mass Spectrometry.

Authors:  Carter K Asef; Kameron M Khaksarfard; Víctor R De Jesús
Journal:  Int J Neonatal Screen       Date:  2016-11-24

Review 2.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

3.  Potential of urinary metabolites for diagnosing multiple sclerosis.

Authors:  Teklab Gebregiworgis; Chandirasegaran Massilamany; Arunakumar Gangaplara; Sivasubramani Thulasingam; Venkata Kolli; Mark T Werth; Eric D Dodds; David Steffen; Jay Reddy; Robert Powers
Journal:  ACS Chem Biol       Date:  2013-02-08       Impact factor: 5.100

4.  Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms.

Authors:  David Cheillan; Marie Joncquel-Chevalier Curt; Gilbert Briand; Gajja S Salomons; Karine Mention-Mulliez; Dries Dobbelaere; Jean-Marie Cuisset; Laurence Lion-François; Vincent Des Portes; Allel Chabli; Vassili Valayannopoulos; Jean-François Benoist; Jean-Marc Pinard; Gilles Simard; Olivier Douay; Kumaran Deiva; Alexandra Afenjar; Delphine Héron; François Rivier; Brigitte Chabrol; Fabienne Prieur; François Cartault; Gaëlle Pitelet; Alice Goldenberg; Soumeya Bekri; Marion Gerard; Richard Delorme; Marc Tardieu; Nicole Porchet; Christine Vianey-Saban; Joseph Vamecq
Journal:  Orphanet J Rare Dis       Date:  2012-12-13       Impact factor: 4.123

5.  Variability of Creatine Metabolism Genes in Children with Autism Spectrum Disorder.

Authors:  Jessie M Cameron; Valeriy Levandovskiy; Wendy Roberts; Evdokia Anagnostou; Stephen Scherer; Alvin Loh; Andreas Schulze
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.